XML Print


Healthy Aging Research Centre, Neyshabur University of Medical Sciences, Neyshabur, Iran
Abstract:   (120 Views)
Introduction: Cutaneous leishmaniasis (CL) due to Leishmania major (L. major) is a widespread vector-borne parasitic infection in subtropical areas. Numerous studies have been conducted to present possible vaccination candidates to address CL. In the present study, 18 L. major vaccine candidate antigens, namely gp46, CatL, CatB, grp78, H1, H2A, H2B, and H4, HSP60, HSP70, HSP83 (HSP90), HSP100, rP0, KMP11, STI-1, TSA, LeIF, and LACK were evaluated by in silico methods to find novel immunogenic epitopes. Methods: online predictions were performed regarding physicochemical, solubility, antigenicity, allergenicity, signal peptide, and transmembrane domains. Since four proteins (i.e., CatB, CatL, gp46, and grp78) were shown to possess signal peptides and transmembrane domains, they were further analyzed along with two antigenic proteins (STI-1 and H2A), regarding post-translational modifications (PTMs), structural (secondary and tertiary) predictions, and epitope mapping for B-cells, cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes against human leukocyte antigen (HLA) reference sets. Results: The world coverage of the CTL and HTL allele-epitope compositions were 96.34% and 41.78%, respectively. Finally, potentially-immunogenic CTL (n = 8) and antigenic HTL (n = 8) epitopes, which were strong IFN-γ inducers, along with 6 B-cell epitopes were selected. Conclusion: These epitopes are potential immunodominant regions among these antigens that upon further evaluations could be considered for a multi-epitope vaccine construction against CL
Full-Text [PDF 1017 kb]   (74 Downloads)    
Type of Study: Research | Subject: Reverse vaccinology
Received: 2024/09/2

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 All Rights Reserved | Vaccine Research

Designed & Developed by : Yektaweb

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.